Also found in: Medical, Wikipedia.


An immunosuppressive drug produced by the actinomycete Streptomyces hygroscopicus, C15H79NO13, used in combination with cyclosporine and corticosteroids to prevent rejection of transplanted tissues or organs. Also called rapamycin.

[si-, origin unknown + (tac)rolimus.]


n sirolimus m, sirolimús m (INN)
Mentioned in ?
References in periodicals archive ?
Move Adds Key Manufacturing Expertise as Company Broadly Advances Sirolimus Clinical Development
Starting in June 2000, all patients also received sirolimus and basiliximab.
today announced that the two companies have entered into a research and development collaboration and license agreement for the Japanese and Asian development and commercialization of sirolimus for the treatment of ocular diseases and conditions including wet age related macular degeneration (wet AMD) and diabetic macular edema (DME).
Maintenance immunosuppression consisted of sirolimus and reduced-dosed tacrolimus.
Wyeth Research also announced it has suspended enrollment in a phase II study comparing sirolimus in combination with tacrolimus/corticosteroids alone in de novo liver transplant patients.
This distinguishes the study from other comparative trials that aimed to assess the differences between Sirolimus and Paclitaxel (having different polymers and different platform).
Describing the cases, the FDA staff members reported that "32 patients were being treated with sirolimus after receiving kidney transplants, one after receiving a liver transplant, and one after receiving a heart transplant.
The potential of sirolimus delivery from a fully-bioresorbable reservoir is exciting and this study is an important step in evaluating its use in the interventional treatment of patients with coronary artery disease," said John Ormiston, M.
Naor will play a key role in MacuSight's ongoing advancement of its sirolimus program, as well as the company's overall scientific direction.
Going forward, the company's clinical program will be heavily focused on the study of sirolimus on its platform, as well as on investigating the vast library of therapeutic agents accessible to its scientists through the research and development programs of pharmaceutical companies in the Johnson & Johnson family of companies.
The active ingredient in LCP-Siro is Sirolimus, an immunosuppressant for the prevention of organ rejection after transplantation and for the treatment of certain autoimmune diseases.